Regeneron Pharmaceuticals is acquiring 23andMe’s health-related assets for $256 million amid concerns over consumer genetic data privacy. The deal is subject to review by a privacy ombudsman, raising questions about data protection and compliance with existing privacy policies. #Regeneron #23andMe
Keypoints
- Regeneron is purchasing 23andMe’s health and research assets to expand its biotech portfolio.
- The deal raises concerns about the security and privacy of consumers’ sensitive genetic data.
- 23andMe will continue offering genetic testing services during the transition.
- A privacy ombudsman will review the transaction to assess its impact on consumer privacy.
- Lawmakers and regulators emphasize that existing privacy policies must be upheld, with concerns about data misuse post-sale.
Read More: https://therecord.media/genetic-testing-sold-millions-privacy